The commentators on this site have not paid attention along the way. The company is getting their product approved by the FDA and after its approved they will get it approved by the TGA. There is no misleading of shareholders. The only comment on misleading is that the CEO wants to ensure he has everything done before we get an announcement. He is s an honest and careful thinker. Plus he has the best pharma advisors in his corner. Wait until he gets an offer to sell the product with a $1b royalty advance !! I suspect we will see such a thing in Q3.
This company is on its way to being a $4-5b company. It’s partnered with experienced firms and is on track to be a winner.
The only new news that is off track is a slight pivot to access the US early access system like we have in Australia using Spontan but renaming it Roxus. It’s an amazingly clever move and will produce revenue short term and will expose the product to the US market.
A1 action and the outcome will increase value immediately. Well done Lee and the company team.
The only reason we have a falling share price is because some unfortunate shareholder had to close their position. That was followed with others getting scared and frighten. Fear feeds fear and share prices go down.
None of the top 20 shareholders have gone anywhere and I am one of them.
Hopefully everyone will understand what I am saying when Lee presents tomorrow.
Try to stop saying dumb things on this site. It’s a waste of time and a reminder nobody has misled you.
LTP Price at posting:
43.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)